486437-10-9

Basic information

• Product Name: Benzenemethanamine, 4-(4-pyridinyl)-
• Synonyms: 4-(4-(pyridin-4-yl)phenyl)methanamine;4-(Pyridine-4-yl)benzylamine;4-(pyridin-4-yl)-benzylamine;4-(4-aminomethylphenyl)-pyridine;[4-(pyridin-4-yl)phenyl]methanamine
• CAS NO: 486437-10-9
• Molecular Formula: C12H12N2
• Molecular Weight: 184.241
• Mol File: 486437-10-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 334.0±30.0 °C(Predicted)
• Density: 1.097±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzenemethanamine, 4-(4-pyridinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 4-(4-pyridinyl)-(486437-10-9)
• EPA Substance Registry System: Benzenemethanamine, 4-(4-pyridinyl)-(486437-10-9)

Safety Data

• Hazardous Substances Data: 486437-10-9(Hazardous Substances Data)

Upstream product

• 623-03-0 4-Cyanochlorobenzene 
• 1692-15-5 4-pyridylboronic acid 
• 144397-70-6 4-(pyridin-4-yl)benzonitrile 
• 126747-14-6 4-cyanophenylboronic acid 
• 3959-07-7 4-Bromobenzylamine 

Downstream Products

• 1094756-96-3 N-(tert-butoxycarbonyl)-N'-bis(3,5-di-tert-butylbenzyl)-N''-[4-(pyrid-4-yl)benzyl]guanidine 
• 1334717-74-6 7-chloro-2-ethyl-N-[4-(pyridin-4-yl)benzyl]imidazo[1,2-a]pyridine-3-carboxamide 
• 1056016-73-9 2-chloro-6-[4-(4-pyridyl)phenylmethylamino]-9-iso-propylpurine 
• 389602-15-7 N-[4-(pyridin-4-yl)-phenylmethyl]-3-(4'-trifluoromethyl-biphenyl-2-carbonylamino)-benzoic acid amide 
• 486435-19-2 N-[4-(pyridin-4-yl)-phenylmethyl]-4-(4'-trifluoromethylbiphenyl-2-carbonylamino)-1-methyl-pyrrole-2-carboxylic acid amide 
• 486434-82-6 N-[4-(pyridin-4-yl)-phenylmethyl]-4-(4'-trifluoromethylbiphenyl-2-carbonylamino)-1-methyl-imidazole-2-carboxylic acid amide 

Relevant articles and documents

Identification of Adenine and Benzimidazole Nucleosides as Potent Human Concentrative Nucleoside Transporter 2 Inhibitors: Potential Treatment for Hyperuricemia and Gout

To test the hypothesis that inhibitors of human concentrative nucleoside transporter 2 (hCNT2) suppress increases in serum urate levels derived from dietary purines, we previously identified adenosine derivative 1 as a potent hCNT2 inhibitor (IC50 = 0.64 μM), but further study was hampered due to its poor solubility. Here we describe the results of subsequent research to identify more soluble and more potent hCNT2 inhibitors, leading to the discovery of the benzimidazole nucleoside 22, which is the most potent hCNT2 inhibitor (IC50 = 0.062 μM) reported to date. Compound 22 significantly suppressed the increase in plasma uric acid levels after oral administration of purine nucleosides in rats. Because compound 22 was poorly absorbed orally in rats (F = 0.51%), its pharmacologic action was mostly limited to the gastrointestinal tract. These findings suggest that inhibition of hCNT2 in the gastrointestinal tract can be a promising approach for the treatment of hyperuricemia.

Synthesis and evaluation of imidazole-4,5-and pyrazine-2,3-dicarboxamides targeting dengue and yellow fever virus

The results of a high-throughput screening assay using the dengue virus-2 replicon showed that the imidazole 4,5-dicarboxamide (I45DC) derivative (15a) has a high dengue virus inhibitory activity. Based on 15a as a lead compound, a novel class of both disubstituted I45DCs and the resembling pyrazine 2,3-dicarboxamides (P23DCs) were synthesized. Here, we report on their in vitro inhibitory activity against dengue virus (DENV) and yellow fever virus (YFV). Some of these first generation compounds have shown activity against both viruses in the micromolar range. Within this series, compound 15b was observed to display the highest antiviral potency against YFV with an EC50 Combining double low line 1.85 μM. In addition, compounds 20a and 20b both potently inhibited replication of DENV (EC50 Combining double low line 0.93 μM) in Vero cells.

Purinenucleoside derivative modified in 8-position and medical use thereof

The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.